GH Research PLC (NASDAQ:GHRS - Get Free Report)'s share price traded up 0.1% during mid-day trading on Friday . The stock traded as high as $9.73 and last traded at $8.98. 44,624 shares were traded during trading, a decline of 44% from the average session volume of 79,020 shares. The stock had previously closed at $8.97.
Analyst Upgrades and Downgrades
Several research firms recently commented on GHRS. JMP Securities reissued a "market outperform" rating and issued a $39.00 target price on shares of GH Research in a report on Wednesday, September 4th. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th.
Get Our Latest Stock Report on GH Research
GH Research Stock Down 3.0 %
The company has a market cap of $452.66 million, a price-to-earnings ratio of -13.40 and a beta of 0.74. The firm has a 50-day simple moving average of $7.75 and a 200 day simple moving average of $10.38.
GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.03. As a group, research analysts expect that GH Research PLC will post -0.85 EPS for the current year.
Institutional Trading of GH Research
An institutional investor recently raised its position in GH Research stock. RA Capital Management L.P. lifted its stake in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 11.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,251,714 shares of the company's stock after purchasing an additional 664,381 shares during the quarter. RA Capital Management L.P. owned about 12.02% of GH Research worth $66,643,000 at the end of the most recent quarter. 56.90% of the stock is owned by hedge funds and other institutional investors.
About GH Research
(
Get Free Report)
GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider GH Research, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GH Research wasn't on the list.
While GH Research currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
